STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GPCR STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

Market Closed 12-12 16:00:00 EST

67.06

-0.38

-0.56%

盘后67.06

+0.000.00%

19:11 EST

High68.91	Low65.81	Vol1.50M
Open68.61	D1 Closing67.44	Amplitude4.60%
Mkt Cap4.64B	Tradable Cap3.29B	Total Shares69.14M
T/O101.15M	T/O Rate3.07%	Tradable Shares49.03M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GPCR","market":"US","secType":"STK","nameCN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","latestPrice":67.06,"timestamp":1765573200000,"preClose":67.44,"halted":0,"volume":1503913,"hourTrading":{"tag":"盘后","latestPrice":67.06,"preClose":67.06,"latestTime":"19:11 EST","volume":15694,"amount":1052417.34,"timestamp":1765584681900},"delay":0,"floatShares":49026700,"shares":69139178,"eps":-3.119226,"marketStatus":"Market Closed","change":-0.38,"latestTime":"12-12 16:00:00 EST","open":68.61,"high":68.91,"low":65.81,"amount":101153233.49739,"amplitude":0.045967,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.119226,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":3,"listingDate":1675400400000,"exchange":"NASDAQ","adjPreClose":67.44,"preHourTrading":{"tag":"盘前","latestPrice":68.89,"preClose":67.44,"latestTime":"09:28 EST","volume":936,"amount":63372.404160000006,"timestamp":1765549690014},"postHourTrading":{"tag":"盘后","latestPrice":67.06,"preClose":67.06,"latestTime":"19:11 EST","volume":15694,"amount":1052417.34,"timestamp":1765584681900},"volumeRatio":0.24313483469960576,"impliedVol":0.7558,"impliedVolPercentile":0.412},"requestUrl":"/m/hq/s/GPCR/tweets","defaultTab":"tweets","newsList":[{"id":"2590505982","title":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505982","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590505982?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:04","pubTimestamp":1765541041,"startTime":"0","endTime":"0","summary":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats upChanges dateline, adds new details in paragraph 19, 20, 27, 36 and 54. The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently dominated by Novo Nordisk NOVOb.CO and Eli Lilly LLY.N.Analysts project the industry could rake in $150 billion in annual sales by the next decade.Soaring demand for its obesity treatment has helped Lilly become the first pharmaceutical company to reach","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL4N3XI0R0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX","LU0345777147.USD","SGXZ99366536.SGD","BK0188","LU1003077747.HKD","MRK","SG9999013999.USD","SG9999002224.SGD","IE00BJLML261.HKD","OPK","LU1989772840.SGD","SRRK","03692","IE00BK4W5M84.HKD","LU0964806797.USD","IE00B4JS1V06.HKD","AZN.UK","03165","LU2106854487.HKD","LU0106261372.USD","LU0211328371.USD","IE0005OL40V9.USD","LU1035775433.USD","IE0002141913.USD","LLY","SG9999015986.USD","AMGN","LU0130517989.USD","LU1720051017.SGD","BK0187","LU1989771016.USD","MTSR","LU0499090636.EUR","ALT","BK4566","SG9999014906.USD","LU1061106388.HKD","IE00BJJMRX11.SGD","00656","LU0256863902.USD","LU1323610961.USD","GPCR","BK0028","600196","IE00BN8TJ469.HKD","LU0306806265.USD","LU0823434583.USD","02105","03933"],"gpt_icon":1},{"id":"2590499345","title":"Press Release: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs","url":"https://stock-news.laohu8.com/highlight/detail?id=2590499345","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590499345?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Dec. 11, 2025  -- Structure Therapeutics Inc. , a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the closing of its previously announced upsized underwritten public offering of 9,961,538 American depositary shares , each representing three ordinary shares, which includes the full exercise of the underwriters' option to purchase up to 1,500,000 additional ADSs at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the securities in the offering were sold by Structure Therapeutics.The gross proceeds to Structure Therapeutics from the offering were approximately $747.5 million, before deducting underwriting discounts and commissions and offering expenses.Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities and BMO Ca","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","LU0795875169.SGD","BK4539","IE00BZ1G4Q59.USD","LU0106831901.USD","LU0234570918.USD","GPCR","LU1989772923.USD","LU2271345857.HKD","LU0557290698.USD","LU0320765646.SGD","LU2023251221.USD","LU0795875086.SGD","BK4007","LU1244550577.SGD","LU0225283273.USD","LU1548497426.USD","LU1668664300.SGD","LU2089284900.SGD","LU0314104364.USD","BK4581","LU0106261372.USD","LU1732800096.USD","LU1791710582.SGD","LU0267386448.USD","LU2028103732.USD","BK4588","LENZ","LU1074936037.SGD","LU0006306889.USD","IE00BKVL7J92.USD","LU2111349929.HKD","LU0912757837.SGD","LU1244550221.USD","LU2133065610.SGD","BK4127","LU0098860793.USD","BK4139","LU0528227936.USD","LU1244550494.USD","LU1732799900.SGD","BK4504","LU2357305700.SGD","LU1720051017.SGD","BK4534","LU1720051108.HKD","LU2089283258.USD","LU0882574139.USD","LU1989772840.SGD","LU0158827781.USD"],"gpt_icon":0},{"id":"2590182805","title":"Structure Therapeutics Inc : Leerink Partners Raises Target Price to  $90.00 From $44.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2590182805","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590182805?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:02","pubTimestamp":1765454572,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH0YC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GPCR","BK4007","BK4599"],"gpt_icon":0},{"id":"2590755847","title":"Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590755847","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590755847?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:01","pubTimestamp":1765400460,"startTime":"0","endTime":"0","summary":"Company will host conference call and live webcast to review and discuss the data at 8:00 am ETNORWOOD, Mass., Dec.  10, 2025  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/10/3203493/0/en/Corbus-Pharmaceuticals-to-Report-Results-from-Phase-1a-Study-of-Oral-CB1-Inverse-Agonist-CRB-913-for-the-Treatment-for-Obesity-on-Thursday-December-11-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","GPCR","CRBP","BK4007","BK4139"],"gpt_icon":0},{"id":"1156240464","title":"Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up over 6%; Novo Nordisk, Roche up Nearly 4%; Eli Lilly up Slightly","url":"https://stock-news.laohu8.com/highlight/detail?id=1156240464","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156240464?lang=en_us&edition=fundamental","pubTime":"2025-12-10 23:21","pubTimestamp":1765380091,"startTime":"0","endTime":"0","summary":"Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up over 6%; Novo Nordisk, Roche up nearly 4%; Eli Lilly up slightly.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"519c241caca73867484fcacc01269b1b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFE","LLY","NVO","AMGN","RHHBY","GPCR","VKTX"],"gpt_icon":0},{"id":"2590583775","title":"Structure Therapeutics Prices $650 Million Upsized Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590583775","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590583775?lang=en_us&edition=fundamental","pubTime":"2025-12-10 18:05","pubTimestamp":1765361145,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) said Wednesday it has priced its upsized public offering of about 8.5 million American depositary shares at $65 per ADS.The company also priced pre-funded warrants to pur","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4599","GPCR","BK4007","BK4139","BK4539","LENZ"],"gpt_icon":0},{"id":"2590110370","title":"Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2590110370","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590110370?lang=en_us&edition=fundamental","pubTime":"2025-12-10 12:15","pubTimestamp":1765340100,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Dec.  09, 2025  (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/10/3202894/0/en/Structure-Therapeutics-Announces-Pricing-of-Upsized-650-Million-Public-Offering-of-ADSs-and-Pre-Funded-Warrants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0528227936.USD","LU1732800096.USD","LU1791710582.SGD","LU0006306889.USD","LU0267386448.USD","BK4534","LU2357305700.SGD","LENZ","IE00BKVL7J92.USD","LU0795875086.SGD","LU1244550494.USD","LU0320765646.SGD","LU2347655156.SGD","LU0158827781.USD","LU1720051108.HKD","LU1668664300.SGD","LU1548497426.USD","LU0106261372.USD","LU2271345857.HKD","BK4139","LU0795875169.SGD","BK4581","LU0098860793.USD","LU1244550577.SGD","LU1363072403.SGD","LU1720051017.SGD","LU0314104364.USD","LU0158827948.USD","LU2111349929.HKD","LU1732799900.SGD","LU2028103732.USD","LU2089283258.USD","BK4504","LU1162221912.USD","LU0971096721.USD","BK4539","LU0882574139.USD","LU2023251221.USD","IE00BZ1G4Q59.USD","BK4007","GPCR","LU2133065610.SGD","LU0557290698.USD","LU1989772840.SGD","BK4585","LU0106831901.USD","LU1791710400.SGD","BK4588","LU0225283273.USD","BK4599"],"gpt_icon":0},{"id":"2590365280","title":"Structure Therapeutics Plans $500 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590365280","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590365280?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:15","pubTimestamp":1765228520,"startTime":"0","endTime":"0","summary":"Structure Therapeutics  said late Monday it plans a public offering of $500 million of American Depositary shares.The company said it plans to grant its underwriters a 30-day option to buy up to an additional $75 million of depository shares.Investors can also buy pre-funded warrants in lieu, it added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4007","LENZ","BK4139","BK4599","GPCR"],"gpt_icon":0},{"id":"2590368764","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2590368764","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590368764?lang=en_us&edition=fundamental","pubTime":"2025-12-09 03:33","pubTimestamp":1765222388,"startTime":"0","endTime":"0","summary":"Top Wealth Group  disclosed late Friday a \"positive\" outlook for the financial year ending Dec. 31, anticipating net profits of not less than $4 million, rebounding from a $2 million loss a year ago.Shares of the company more than doubled as intraday trading volume catapulted to over 16.5 million from a daily average of about 249,000.Wave Life Sciences  said Monday that interim data from its phase 1 trial of WVE-007, an obesity treatment, showed improvements in body composition.The weight loss was similar to GLP-1, but without muscle loss, the company added.Shares of the company soared 140% as intraday trading volume surged to over 119 million from a daily average of roughly 2.6 million.Structure Therapeutics  disclosed on Monday that its obesity drug candidate aleniglipron achieved statistical significance in the phase 2b trial's primary and key secondary endpoints.Shares of the company surged 99% as intraday trading volume climbed to more than 16.1 million from a daily average of abo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GPCR","BK4212","WVE","BK4007","BK4599","TWG"],"gpt_icon":0},{"id":"2590368328","title":"BUZZ-U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart","url":"https://stock-news.laohu8.com/highlight/detail?id=2590368328","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590368328?lang=en_us&edition=fundamental","pubTime":"2025-12-09 02:45","pubTimestamp":1765219558,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Five Below, Boeing, InstacartEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: http","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL6N3XE0MP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COP","RIOT","OMF","SCCO","WBD","CVX","FIVE","TPL","ROK","NRIX","CFLT","INCY","GM","XOM","OCUL","FANG","CRH","DYN","AGIO","EOG","LEN","AR","LNG","ALB","FCX","FULC","NEE","APD","BKR","MMM","USCB","EXE","WYNN","GPCR","HUT","KYMR","COMP","JEF","ACLX","APA"],"gpt_icon":1},{"id":"2590236880","title":"Sector Update: Health Care Stocks Lower in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2590236880","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590236880?lang=en_us&edition=fundamental","pubTime":"2025-12-09 02:43","pubTimestamp":1765219408,"startTime":"0","endTime":"0","summary":"Health care stocks declined Monday afternoon, with the NYSE Health Care Index down 1% and the Health Care Select Sector SPDR Fund  falling 1%.The iShares Biotechnology ETF  decreased 0.6%.In corporate news, STAAR Surgical  shares fell 4% after the company said Monday the go-shop period under its merger agreement with Alcon  has expired with no competing proposals received. Alcon was down 1.9%.PROCEPT BioRobotics  still has a large market opportunity for its aquablation technology to treat benign prostatic hyperplasia, but utilization growth has slowed, BofA Securities said in a research report. The brokerage downgraded the stock to neutral from buy and lowered its price target to $38 per share from $55. PROCEPT shares dropped 4.8%.Wave Life Sciences  shares soared 129% after the company said interim data from its phase 1 trial of WVE-007 to treat obesity showed improvements in body composition, with weight loss similar to GLP-1, but without muscle loss, at three months compared to base","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4581","LABU","IBB","BK7094","BK4007","BK4585","BK4198","BK4599","PRCT","BK4082","WVE","BK4534","ALC.AU","BK4548","BK4588","LU2324357040.USD","LU2265009873.SGD","STAA","XLV","GPCR","ALC","LU1804176565.USD","XBI"],"gpt_icon":0},{"id":"2590350256","title":"What's Going On With Structure Therapeutics (GPCR) Stock Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590350256","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590350256?lang=en_us&edition=fundamental","pubTime":"2025-12-09 02:05","pubTimestamp":1765217100,"startTime":"0","endTime":"0","summary":"Shares of Structure Therapeutics are soaring Monday after the company reported positive topline data from a weight loss drug trial.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/08/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/08/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49264353/whats-going-on-with-structure-therapeutics-gpcr-stock-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49264353/whats-going-on-with-structure-therapeutics-gpcr-stock-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4007","BK4599","GPCR"],"gpt_icon":0},{"id":"2589227354","title":"Structure Therapeutics Shares Surge on Positive Phase 2b Results for Obesity Drug Aleniglipron","url":"https://stock-news.laohu8.com/highlight/detail?id=2589227354","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589227354?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:47","pubTimestamp":1765208830,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) shares almost doubled in recent Monday trading after the company reported that its obesity drug candidate aleniglipron achieved statistical significance in the Phase 2b s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4599","BK4139","LENZ","GPCR","BK4007","BK4539"],"gpt_icon":0},{"id":"2589359780","title":"BUZZ-U.S. STOCKS ON THE MOVE-Micron, NextEra Energy, Ocular Therapeutix","url":"https://stock-news.laohu8.com/highlight/detail?id=2589359780","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589359780?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:34","pubTimestamp":1765204451,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Micron, NextEra Energy, Ocular TherapeutixEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call new","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL6N3XE0MO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBM","ACLX","APA","LEN","MU","FANG","INCY","CFLT","LU0661504455.SGD","LU1261432733.SGD","FCX","EOG","ALB","RIO.UK","BK4539","TSYW.SI","AR","WYNN","GM","USCB","AGIO","CRH","RIO.AU","SCCO","CVNA","KYMR","DYN","FULC","BHP.AU","COP","JEF","OCUL","GPCR","WVE","RIOT","MMM","NEE","HUT","COMP"],"gpt_icon":1},{"id":"2589359274","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:33 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2589359274","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589359274?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:33","pubTimestamp":1765204434,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:33 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nAQN2LCINL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GPCR","BK4599"],"gpt_icon":0},{"id":"2589592193","title":"Structure Therapeutics Shares Jump 40.3% After Promising Mid-Stage Data for Its Weight-Loss Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2589592193","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589592193?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:32","pubTimestamp":1765204335,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE10S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","GPCR","BK4007"],"gpt_icon":0},{"id":"2589356204","title":"Structure details positive trial data for a weight-loss pill, and the stock rockets","url":"https://stock-news.laohu8.com/highlight/detail?id=2589356204","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589356204?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:12","pubTimestamp":1765203120,"startTime":"0","endTime":"0","summary":"The biopharma company now plans to start a Phase 3 trial for the drug next year. Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron.Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly's experimental weight-loss pills.The biopharmaceutical company , which went public in early 2023, is one of only a few independent obesity biotechs with later-stage drugs in development. Investors have been waiting for the Phase 2b readout to understand if aleniglipron has the potential to serve as a \"scaffold\" for Structure's portfolio, according to Stifel analysts.The stock shot up 31.5% in premarket trading, as it heads toward the biggest one-day gain since the record 54.2% rally seen on June 3, 2024. The stock was on track to open around the highest levels seen since June 2024.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Structure details positive trial data for a weight-loss pill, and the stock rockets","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131342.USD","LU0058720904.USD","LU2552382132.HKD","LU0417517546.SGD","LU0456855351.SGD","LU1551013342.USD","LU0466842654.USD","LU1548497426.USD","LU2237443895.HKD","BK4516","LU1267930730.SGD","LU0708995401.HKD","IE00BJJMRZ35.SGD","LU0385154629.USD","BK4581","SGXZ99366536.SGD","LU0320765992.SGD","LU1232071149.USD","LU0316494557.USD","LU0289739699.SGD","LU1023059063.AUD","LU1127390331.HKD","LU2491050071.SGD","GB00BDT5M118.USD","IE00BJT1NW94.SGD","SG9999001176.SGD","LU2750360641.GBP","IE0004445015.USD","SG9999015978.USD","LU2471134796.USD","LU1983299246.USD","LU0256863902.USD","SG9999014898.SGD","LU1035775433.USD","IE00B2B36J28.USD","BK4585","LU0203201768.USD","LU0238689110.USD","LU1280957306.USD","IE00BJJMRY28.SGD","LU1366192091.USD","LU1551013425.SGD","IE00BKDWB100.SGD","LU0096364046.USD","LU1868837136.USD","LU2106854487.HKD","LU0353189680.USD","LU2552382215.SGD","LU2361044865.SGD","LU0061475181.USD","LU0006306889.USD","LU1868836757.USD","LU2357305700.SGD","LU1804176565.USD","BK4533","LU2361045086.USD","LU2237443549.SGD","LU2087625088.SGD","LU0354030438.USD","SGXZ51526630.SGD","LU0882574055.USD","LU1720051108.HKD","LU0234572021.USD","LU2468319806.SGD","LU2552382058.USD","LU2461242641.AUD","LU0106261372.USD","LU1868836591.USD","SG9999013999.USD","LU0266013472.USD","LU0672654240.SGD","IE0005OL40V9.USD","IE00BFTCPJ56.SGD","LU2237443622.USD","LU2360106947.USD","LU0471298777.SGD","SG9999018865.SGD","LU0094547139.USD","LU2746668974.SGD","LU1323610961.USD","LU2471134952.CNY","SG9999014906.USD","IE00B7KXQ091.USD","LU1093756168.USD","LU2456880835.USD","LU2237438978.USD","BK4007","LU2237443978.SGD","LU0114720955.EUR","LU0323591593.USD","LU0640476718.USD","LU0823434740.USD","LU0354030511.USD","LU2491050154.USD","LU1989771016.USD","LU2491049909.HKD","LU1868837300.USD","LU0471298694.HKD","LU0820561909.HKD","SGXZ81514606.USD","BK4534","LU2324357040.USD","LU0943347566.SGD","LU2417539215.USD","LU1868836914.USD","LU2471134879.HKD","LU1291159041.SGD","LU2471134523.USD","LU0320765059.SGD","SG9999015945.SGD","SG9999014914.USD","LU2108987350.USD","IE0009355771.USD","IE00B4JS1V06.HKD","LU2602419157.SGD","LU1974910355.USD","LU1720051017.SGD","LU2265009873.SGD","LU2023250504.SGD","LU2089984988.USD","LU2264538146.SGD","LU2168563687.JPY","LU0256863811.USD","LU2462157665.USD","IE00BK4W5M84.HKD","SGXZ57979304.SGD","LU0079474960.USD","LU2361044949.HKD","LU2746668461.USD","GPCR","LU1057294990.SGD","LU2168564065.EUR","LU2168564495.EUR","IE00B4R5TH58.HKD","LU0820561818.USD","LU1061106388.HKD","BK4588","LU1917777945.USD","BK4599","IE00BJLML261.HKD","IE0004445239.USD","SG9999017495.SGD","LU2063271972.USD","LU0109394709.USD","IE00B1BXHZ80.USD","LU0353189763.USD","IE00BFSS8Q28.SGD","IE0002141913.USD","SGXZ31699556.SGD","IE00BN29S564.USD","LU0198837287.USD","LU2112291526.USD","LU2168564149.EUR","LU2237443465.HKD","LU0823416689.USD","LU0432979614.USD","LU0889565916.HKD","LU1814569148.SGD","LU2750360997.AUD","LU0689472784.USD","SG9999015952.SGD","IE00B1XK9C88.USD","IE00BFSS7M15.SGD","LU2236285917.USD","SG9999018857.SGD","LU0823434583.USD","LU2237443382.USD","IE00BJJMRX11.SGD","LU1093756325.SGD","IE00BKPKM429.USD","LU1069344957.HKD","SG9999001176.USD","LU0882574139.USD","LU1623119135.USD","IE00BWXC8680.SGD","LU0122379950.USD","LU0786609619.USD","SG9999014880.SGD","SG9999015986.USD","LU1988902786.USD","LU0109391861.USD","LU0097036916.USD","IE00BK4W5L77.USD","LU2211815571.USD","IE00B775H168.HKD","LU2168564222.USD","LU0203202063.USD","LU1712237335.SGD"],"gpt_icon":0},{"id":"2589335319","title":"Structure Therapeutics Shares Reverse Course, Last Down 15% Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2589335319","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589335319?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:13","pubTimestamp":1765199597,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL4N3XE0YN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GPCR","BK4007","BK4599"],"gpt_icon":0},{"id":"2589524353","title":"Structure's experimental pill shows 11% weight loss in study, shares up","url":"https://stock-news.laohu8.com/highlight/detail?id=2589524353","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589524353?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:04","pubTimestamp":1765199092,"startTime":"0","endTime":"0","summary":"Structure's experimental pill shows 11% weight loss in study, shares upDec 8  - Structure Therapeutics GPCR.O said on Monday that its obesity pill showed a 11.3% reduction in weight in a mid-stage study.Shares of the biotech jumped 41.8% in premarket trading.  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL4N3XE0X5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4599","BK4007"],"gpt_icon":0},{"id":"2589353548","title":"Structure Therapeutics Shares Jump 30% Premarket After Data for Its Weight-Loss Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353548?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:04","pubTimestamp":1765199075,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL4N3XE0X9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","GPCR","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.structuretx.com","stockEarnings":[{"period":"1week","weight":0.9404},{"period":"1month","weight":0.8669},{"period":"3month","weight":2.2071},{"period":"6month","weight":2.0932},{"period":"1year","weight":1.1148},{"period":"ytd","weight":1.4727}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.","exchange":"NASDAQ","name":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","nameEN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD,GPCR,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票老虎,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票老虎国际,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD行情,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票行情,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股价,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股市,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票价格,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票交易,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票购买,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction